Monthly Horizon Scanning Report – January 2023
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Estradiol spray for the treatment of menopausal symptoms
New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.
Download the full review below to read more.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation
Prescribing Update Newsletter – January 2022
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
This month’s edition covers the use of steroid medication warning cards for children and young people, National Detect, Protect and Perfect programme and choice of DOACs, Primary Care Discussions: Focus on Diabetes, and SPS: New guides for providing medicines advice and/or prescribing in pregnancy. It also continues a series of spotlight articles on one of the types of RDTC stakeholder level report; this month looks at the new Monthly Formulary Amendments report.
Monthly Formulary Amendments – January 2022
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, RMOC Guidance, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
It includes a suggested formulary position for APCs/Formulary Committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders.
Monthly Horizon Scanning Report – January 2022
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies
This information is produced for use by NHS healthcare professionals.
Prescribing Update Newsletter – January 2021
Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.
If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net
Monthly Horizon Scanning Report – Jan 2021
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licenses, significant new guidance, and decisions that have been made by recognised bodies.
This information is produced for use by NHS healthcare professionals.
Impact of Priadel Price Change on CCG Prescribing Budgets
This bulletin aims to raise awareness of the NHS price increase for Priadel® (lithium carbonate) tablets as of November 2020 and the resulting cost impact to primary care. While discussions between the DHSC and the manufacturer of Priadel have prevented its discontinuation from the UK market at this stage, the renegotiated price in November 2020 has seen the cost more than double from December 2020.
There are three versions of this publication; please select the appropriate version for your region below.
Cardiovascular outcomes associated with SGLT2 inhibitors (update 2)
Overview
Medicines in Practice is a series of evidence–based publications specifically designed to support stakeholder medicines optimisation services. The series aims to maximise health gains through the optimum use of medicines, by influencing and changing prescribing behaviour.
The sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population at increased risk of cardiovascular events. Recent clinical trials and cohort studies have assessed whether the SGLT2 inhibitors reduce this risk.
Download the full review below to read more.
Antibiotic use in children: liquid vs. solid oral dosage forms
This bulletin addresses cost-effective prescribing of oral antimicrobials in children without dysphagia. Liquid antimicrobial preparations are significantly more expensive than solid oral dosage forms, so the bulletin aims to
present the current prescribing patterns of antimicrobial formulations in the paediatric population on a CCG Level.
This review is older than 18 months; in view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature.
There are three versions of this publication; please select the appropriate version for your region below.